Ángel Martínez-Brotons

Carbohydrate Antigen 125: An Emerging Prognostic Risk Factor in Acute Heart Failure?

Objective: To assess whether circulating levels of carbohydrate antigen 125 (CA125) predict subsequent 6-month all-cause mortality in patients after the index hospitalisation for acute heart failure (HF). Design and setting: Prospective cohort study at a single teaching centre in Spain. Methods: 529 consecutive patients with acute HF admitted in a single university centre were analysed. In addition to the traditional clinical information, CA125 (U/ml) was measured during the early course of hospitalisation. The independent association between baseline CA125 and mortality was assessed with Cox regression analysis. The follow-up was limited to 6 months. Results: 349 (66%) patients showed serum levels of CA125 >35 U/ml (established cut-off point value). At a 6-month follow-up, 89 (16.8%) deaths were identified. A positive trend between mortality and CA125 quartiles was observed; 3.8%, 15.2%, 22% and 26.5% of deaths occurred from quartile 1 to 4 of CA125 (p<0.001). Likewise, a monotonic, ascending trend in the risk ratios was estimated from the multivariable Cox model. Compared with the first quartile of CA125, the HRs (95% CI) for the second, third and fourth quartiles were 3.25 (1.20 to 8.79), 4.91 (1.88 to 12.85) and 8.41 (3.24 to 21.79), respectively. Conclusions: Serum levels of CA125 obtained in patients admitted with a diagnosis of acute HF was shown to be an independent predictor of mortality up to the 6-month follow-up.

Implantation of single-lead atrioventricular permanent pacemakers guided by electroanatomic navigation without the use of fluoroscopy

AIMS Fluoroscopy is the standard and almost unique tool used for cardiac imaging during permanent pacemaker implantation, and its use implies exposure of patients and operators to radiation. The usefulness for this purpose of electroanatomic systems not based on fluoroscopy is unknown. Our aim was to study the feasibility of implanting single-lead VDD pacemakers without the use of fluoroscopy. METHODS AND RESULTS EnSite NavX, a catheter navigation tool based on the creation of a voltage gradient across the thorax of the patient, was used as an exclusive imaging tool during the implantation of single-lead atrioventricular (VDD) permanent pacemakers in 15 consecutive patients with atrioventricular block and normal sinus node function. A retrospective series of 15 consecutive patients in whom VDD pacemakers were implanted under fluoroscopic guidance was used as a control group. The pacemaker could be implanted in all patients. Time spent to obtain the right ventricle anatomy was 10.1 +/- 5.4 min and time to place the lead in an adequate position was 10.1 +/- 7.8 min. Total implant time was 59.3 +/- 15.6 min (51.5 +/- 12.3 min in the control group; P = 0.14). In one patient, a short pulse of radioscopy was needed for a correct catheterization of the subclavian vein. No complications were observed during the procedure. One lead dislodgement that required re-operation was detected 24 h after implantation. At 3 months follow-up, all pacemakers were functioning properly, with adequate pacing and sensing thresholds. CONCLUSION Electroanatomic navigation systems such as NavX can be used for cardiac imaging during single-lead atrioventricular pacemaker implantation as a reliable and safe alternative to fluoroscopy.

Significance of tilt table testing in patients with suspected arrhythmic syncope and negative electrophysiologic study.

Background: The diagnostic significance of a tilt table test (TTT) in patients with a suspected arrhythmic etiology for syncope and negative electrophysiologic study (EPS) has not been previously assessed comparing the TTT results with the findings of prolonged monitoring using an implantable loop recorder (ILR). We sought to assess the diagnostic yielding of TTT in patients with suspected arrhythmic syncope and negative EPS.

Síncope y bloqueo de rama. Rendimiento del uso escalonado del estudio electrofisiológico y de la monitorización electrocardiográfica prolongada

INTRODUCTION AND OBJECTIVES The objective of this study was to determine the diagnostic yield of a stepped protocol involving an electrophysiologic study (EPS) and implantable loop recorders (ILR) in patients with syncope and bundle branch block (BBB). METHODS Eighty-five consecutive patients referred for syncope and BBB after initial non-diagnostic assessment underwent EPS including a pharmacological challenge with procainamide. Those patients without indication for defibrillator implantation received ILRs. Follow-up continued until diagnosis or end of battery life. RESULTS The EPS was diagnostic in 36 patients (42%). The most frequent diagnoses were paroxysmal atrioventricular block (AVB) (n=27), followed by ventricular tachycardia (VT) (n=6). All patients with VT had structural heart disease; left BBB was more prevalent in this group. Thirty-eight patients received ILRs and diagnosis was achieved in 13 (34%) of them; paroxysmal AVB (n=10) was the most frequent diagnosis. Median follow-up to diagnosis of paroxysmal AVB was 97 days (interquartile range 60-117 days). Paroxysmal AVB was more frequent in patients with right BBB and prolonged PR interval and/or axis deviation. We found no occurrence of VT or arrhythmic death during follow-up. CONCLUSIONS The most common etiology of syncope in patients with BBB was paroxysmal AVB, followed by VT. The stepped use of EPS and ILR in negative patients enables us to safely achieve a high diagnostic yield, given that VT is usually diagnosed during EPS.

Relationship of C-Reactive Protein Levels With Angiographic Findings and Markers of Necrosis in Non-ST-Segment Elevation Acute Coronary Syndrome

INTRODUCTION AND OBJECTIVES The mechanism responsible for elevated C-reactive protein levels (inflammation of the ruptured atherosclerotic plaque or myocardial necrosis) in acute coronary syndromes is controversial. The aim of this study was to investigate the relationship between C-reactive protein levels and angiographic complexity of the culprit lesion and troponin elevation in patients with non-ST elevation acute coronary syndromes. PATIENTS AND METHOD The study group consisted of 125 patients with single-vessel disease. Troponin-I and C-reactive protein were measured, and the complexity of the culprit lesion was analyzed (TIMI flow and thrombus). Information on age, sex, smoking habit, hypertension, hypercholesterolemia and diabetes was obtained from the medical record. RESULTS The quartile distribution of C-reactive protein showed more patients with TIMI flow < 3 (31%, 28%, 18%, and 55%; P=.02), thrombus (3%, 6%, 7%, and 28%; P=.007) and troponin-I elevation (19%, 44%, 50%, and 66%; P=.003) in the fourth quartile. Multivariate analysis showed both thrombus (OR = 4.1; 95% CI, 1.2-14.3; P=.03) and troponin elevation (OR = 2.6; 95% CI, 1.1-6.3; P=.03) to be associated with C-reactive protein > 18 mg/L (fourth quartile cut-off). When treated as a continuous variable, higher levels of C-reactive protein were also associated with thrombus (P=.02) and troponin elevation (P=.003). No other clinical variables were related with C-reactive protein levels. CONCLUSIONS Both angiographic complexity of the culprit lesion and elevated troponin level are related with increased C-reactive protein levels in non-ST elevation acute coronary syndromes.

Experience in Daily Clinical Practice of Ambulatory Cardioversion of Atrial Fibrillation Treated With New Oral Anticoagulants

Atrial fibrillation (AF) is the most common type of sustained arrhythmia in our setting. Cardioversion of AF persisting for more than 48 hours requires prior oral anticoagulation to minimize the risk of thromboembolic events associated with the procedure. In this context, new oral anticoagulants (NOACs) have recently emerged as an alternative to the classic use of oral anticoagulation with vitamin K antagonists (VKAs), based on their efficacy and safety vs warfarin in cardioversion substudies of clinical trials on stroke prevention in nonvalvular AF. However, little is known about their safety in daily clinical practice, and there are no published data in our environment beyond the setting of randomized clinical trials. We conducted a retrospective observational study of all cases of ambulatory cardioversion for AF performed at the Hospital Clı́nico Universitario de Valencia between 1 January 2012 and 1 April 2014. The type of anticoagulant therapy (VKAs or NOACs) was decided by the physician requesting cardioversion. In the case of VKAs, the patient required at least 2 international normalized ratio (INR) values 2 and at least 3 weeks of treatment. In the case of NOACs, patients required treatment for at least 3 weeks and were monitored to ensure adherence. All NOAC dosages and posology were required to match those used in the clinical trials that compared these drugs with warfarin in nonvalvular AF. We analyzed the incidence of thromboembolic events (stroke or systemic embolism [SE]) for 30 days after the procedure. Stroke was defined as the sudden appearance of a

Rendimiento terapéutico de un protocolo prospectivo de cardioversión en la fibrilación auricular persistente

Introduction and objectives. The best therapeutic approach for persistent atrial fibrillation has yet to be defined. Our aim was to investigate the effects of cardioversion in unselected patients with persistent atrial fibrillation who were treated according to a strict protocol involving pretreatment, cardioversion, and follow-up. Methods. Consecutive patients with persistent atrial fibrillation of at least 1 months’ duration were included prospectively in a cardioversion protocol that involved standard antiarrhythmic pretreatment, with amiodarone being offered first, and follow-up. Results. The study included 295 patients, 87.5% of whom were taking the antiarrhythmic drug amiodarone. Sinus rhythm was restored in 92.5%, with pharmacologic cardioversion occurring in 9.5%. The recurrence rate was 33.5% in the first month and 54.9% by month 12. Antiarrhythmic treatment had to be modified in 10.8% of patients. Independent risk factors for recurrence during the first year after cardioversion were an atrial fibrillation duration greater than 1 year, previous cardioversion, and left ventricular dilatation. A simple risk scoring system was able to differentiate between subgroups of patients with a low, intermediate or high risk of recurrence in the first year after cardioversion. Conclusions. Sinus rhythm was maintained for 1 year after effective cardioversion in 45.1% of patients who received homogeneous antiarrhythmic pretreatment. There were few side effects. Recurrence can be predicted using clinical variables such as left ventricular dilatation, arrhythmia duration, and previous cardioversion.

Spanish Catheter Ablation Registry. 17th Official Report of the Spanish Society of Cardiology Working Group on Electrophysiology and Arrhythmias (2017)

INTRODUCTION AND OBJECTIVES This report describes the findings of the 2017 Spanish Catheter Ablation Registry. METHODS Data collection was retrospective. A standardized questionnaire was completed by each of the participating centers. RESULTS A total of 15 284 ablation procedures were performed by 98 institutions (the highest number of ablations and institutions historically reported in this registry), with a mean of 156±126 and a median of 136 procedures per center. For the first time, the most frequently treated ablation target was atrial fibrillation (n=3457; 22.6%), followed by cavotricuspid isthmus (n=3449; 22.5%) and atrioventricular nodal re-entrant tachycardia (n=3429; 22.4%). The overall success rate was 87%. The rate of major complications was 2.6%, and the mortality rate was 0.09%. The percentage of procedures performed without fluoroscopic support increased to 6% of all ablations, and 2.3% of all ablations were performed in pediatric patients. CONCLUSIONS The Spanish Ablation Catheter Registry systematically and uninterruptedly collects data on the ablation procedures performed in Spain, revealing that both the number of ablations and the number of centers performing them has progressively increased, while maintaining a high success rate and a low percentage of complications.